8-K: Seres Therapeutics Q1 2026 Update: Clinical Milestones and Financials

Seres Therapeutics reported Q1 2026 financial results, highlighting upcoming clinical readouts for SER-155 and advancing its I&I pipeline, while managing operational expenses and seeking capital.

Summary

• Seres Therapeutics announced its first quarter 2026 financial results and provided business updates.
• The company is anticipating a clinical readout in the coming weeks from an investigator-sponsored study evaluating SER-155 for immune checkpoint inhibitor-related enterocolitis (irEC).
• Seres is also advancing its inflammatory and immunology programs, including SER-603 for inflammatory bowel disease (IBD), with IND-enabling work underway.
• SER-155 is Phase 2 ready for preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT), with funding being sought.
• The company reported a net loss of $19.9 million for Q1 2026, compared to a net income of $32.7 million in Q1 2025, which included a $50 million installment payment from Nestl.
• Operating expenses were approximately $6 million lower in Q1 2026 compared to Q1 2025.
• As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents, with an expected operational runway through the third quarter of 2026.
• The company is actively pursuing partnerships and other financing sources to support pipeline advancement.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant net loss, reduced cash position, and limited operational runway, despite positive clinical development updates and cost management efforts.

Positives

• Upcoming clinical readout for SER-155 in irEC, a serious condition with meaningful therapeutic and commercial opportunity.
• Advancement of SER-603 for IBD with IND-enabling activities progressing.
• SER-155 is Phase 2 ready for preventing bloodstream infections in allo-HSCT patients.
• Operating expenses were approximately $6 million lower in Q1 2026 compared to Q1 2025.
• Positive preclinical data for SER-603 presented at Digestive Disease Week (DDW).
• Publication of manuscripts in Nature Medicine and Journal of Infectious Diseases highlighting functional mechanism and clinical impact of VOWST.
• Significant and durable shift in GI microbiome composition observed in SER-155 Phase 1b study, associated with reduced bloodstream infection incidence.

Negatives

• Net loss of $19.9 million for Q1 2026, a significant decrease from the net income of $32.7 million in Q1 2025.
• Cash and cash equivalents of $29.8 million as of March 31, 2026, with an expected operational runway only through Q3 2026.
• Need to secure funding to commence Phase 2 study for SER-155 in allo-HSCT.
• Research and development expenses increased to $13.2 million in Q1 2026 from $11.8 million in Q1 2025, partly due to manufacturing costs not reimbursed by Nestl.
• The company has incurred significant losses and is not currently profitable.

Risks

• Need for additional funding to continue operations and advance the pipeline.
• Ability to continue as a going concern.
• Incurrence of significant losses and potential inability to become profitable.
• Cost reduction actions may not achieve intended benefits or extend cash runway.
• Reliance on third parties for clinical trials and manufacturing.
• Potential for failure to satisfy continued listing rules from The Nasdaq Stock Market LLC.
• Competition in the biotherapeutics market.
• Risks and uncertainties associated with the VOWST sale and potential challenges as a smaller company.

Future Outlook

The company expects to fund operations through the third quarter of 2026 and is actively pursuing partnerships and other financing sources to extend its cash runway and support pipeline advancement. Upcoming clinical readouts for SER-155 are anticipated in the coming weeks, and IND-enabling work for SER-603 is progressing.

Management Comments

• "We are approaching an important clinical milestone with the expected readout in the coming weeks from the investigator-sponsored study at Memorial Sloan Kettering Cancer Center, an institution with whom we’ve collaborated for over a decade, evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC)."
• "irEC is a serious condition which represents a meaningful therapeutic and commercial opportunity, and with positive data we will evaluate potential development pathways and adjacent expansion opportunities."
• "In parallel, we are advancing our inflammatory and immunology portfolio, including SER-603 for inflammatory bowel disease, with IND-enabling work progressing."
• "We have achieved Phase 2 readiness for SER-155 for the prevention of bloodstream infections in patients undergoing allo-HSCT for the treatment of blood cancer and are seeking funding to commence the study."
• "We are continuing disciplined capital allocation while actively pursuing partnerships and other financing sources to support Seres pipeline advancement and long-term value creation."

Industry Context

StockSavvy.ai notes that Seres Therapeutics is navigating a challenging biotech funding environment, focusing on advancing its live biotherapeutic pipeline in inflammatory and immune diseases. The upcoming clinical data for SER-155 is critical for demonstrating the platform's potential and attracting further investment or partnerships.

Related Party Transactions

• Accounts receivable due from SPN - related party: $360 thousand as of March 31, 2026.
• Accrued liabilities due to SPN - related party: $3,278 thousand as of March 31, 2026.
• Reimbursements from SPN (related party) for transition services provided by the Company were $0 for Q1 2026 and $6,309 thousand for Q1 2025.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, but also potential upside if clinical milestones are met and funding is secured.
• Employees: Continued focus on operational efficiency and pipeline advancement, but potential uncertainty due to funding needs.
• Creditors: The company's ability to continue as a going concern is a key consideration.

Next Steps

• Receive clinical readout from investigator-sponsored SER-155 study in irEC.
• Continue IND-enabling activities for SER-603.
• Secure funding to commence Phase 2 study for SER-155 in allo-HSCT.
• Actively pursue partnerships and other financing sources to extend cash runway.

Key Dates

Recommendation

The company is at a critical juncture with upcoming clinical data for SER-155 and a pressing need for funding. While there are positive developments in the pipeline and cost management, the financial precariousness warrants a 'hold' recommendation until further clarity on funding and clinical outcomes is achieved.

Keywords

Seres Therapeutics, SER-155, SER-603, Live Biotherapeutics, Microbiome, Inflammatory Bowel Disease, Enterocolitis, Financial Results